
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is well-positioned for long-term success with its transformative solutions in urology and its focus on BPH. Upside risks to the company include better procedure volumes, higher average selling prices, and potential acquisition. On the other hand, potential challenges could arise from slower procedure growth or reimbursement changes for the competing PAE treatment. Despite these uncertainties, the company has reiterated its strong financial outlook for the year, with revenue growth and improved margins expected. Additionally, recent capital placements signal high demand for the company's technology, and its stock currently undervalues future growth potential, making it a sound investment choice.
Bears say
PROCEPT BioRobotics is facing a slowing procedure growth, primarily due to increased competition and restructuring within the company's sales force. While new leadership has put forth initiatives to increase system utilization, it remains to be seen if they will be successful and if so, how long it will take to have an impact. With a significant increase in competition and potential headwinds from rising adoption of a competing procedure, there are concerns about the company's ability to meet its procedure growth targets, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares